Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
3 SEHK Growth Stocks With High Insider Ownership

In This Article:

The Hong Kong market has faced a challenging environment recently, with the Hang Seng Index declining amid weak manufacturing data and broader economic concerns. Despite these headwinds, growth companies with high insider ownership can present unique opportunities for investors, as significant insider stakes often signal confidence in the company's long-term prospects. In this article, we will explore three growth stocks listed on the SEHK that exhibit high levels of insider ownership. These companies stand out not only for their potential to grow but also because their leadership teams have substantial personal investments at stake, aligning their interests closely with those of other shareholders.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

18.8%

104.1%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

Tian Tu Capital (SEHK:1973)

34%

70.5%

Fenbi (SEHK:2469)

31.1%

42.8%

Adicon Holdings (SEHK:9860)

22.4%

28.3%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.7%

79.3%

DPC Dash (SEHK:1405)

38.2%

91.4%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

100.1%

Ocumension Therapeutics (SEHK:1477)

23.3%

93.7%

Beijing Airdoc Technology (SEHK:2251)

28.6%

83.9%

Click here to see the full list of 54 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

LifeTech Scientific

Simply Wall St Growth Rating: ★★★★☆☆

Overview: LifeTech Scientific Corporation develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases globally, with a market cap of HK$7.41 billion.

Operations: The company generates revenue from three primary segments: CN¥495.67 million from the Structural Heart Diseases Business, CN¥707.11 million from the Peripheral Vascular Diseases Business, and CN¥64.40 million from the Cardiac Pacing and Electrophysiology Business.

Insider Ownership: 16%

LifeTech Scientific, a growth company with high insider ownership, recently announced promising one-year follow-up results for its IBS ® Coronary Scaffold, demonstrating comparable safety and effectiveness to existing drug-eluting stents. The company's revenue is forecasted to grow at 16.8% annually, outpacing the broader Hong Kong market's growth rate of 7.4%. Earnings are expected to rise significantly over the next three years at 20.5% per year. Recent bylaw amendments also indicate strategic corporate governance adjustments.